Formulary Watch |

All News - Page 73

Pharma makers pull MS drug from worldwide market
Pharma makers pull MS drug from worldwide market
March 5, 2018
In a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis after reports of serious brain inflammation in patients.
Top 3 new cancer drugs
Top 3 new cancer drugs
March 5, 2018
The first radioactive drug to treat a certain type of cancer is among the top 3 new drug approvals for cancer. Here are the other top cancer drug approvals so far in 2018.
FDA warns about opioid-containing supplement
FDA warns about opioid-containing supplement
February 26, 2018
FDA said the manufacturer of dietary supplements containing kratom, a natural opioid used to treat opioid use disorder, agreed to destroy the supplements, and is again warning the public about kratom.
Patient group pushes FDA to improve biosimilar education
Patient group pushes FDA to improve biosimilar education
February 20, 2018
FDA should provide better education about biosimilar drugs on the agency’s web site dedicated to biosimilars, a patient advocacy group said.
3 new FDA drug approvals
3 new FDA drug approvals
February 20, 2018
FDA recently approved 3 major drugs to treat lung cancer, prostate cancer, and cystic fibrosis. Here are the top 3 new drug approvals.
Opioid prescription limits gain support
Opioid prescription limits gain support
February 12, 2018
A pharmacist organization is among the supporters of a new Medicare Part D proposal, which calls for a 7-day supply limit on opioid prescriptions.
DEA tightens fentanyl scheduling
DEA tightens fentanyl scheduling
February 12, 2018
Due to the increased use of illicit fentanyl mixed with heroin and used in counterfeit prescription drugs, the DEA placed all illicit fentanyl analogues not already regulated by the Controlled Substances Act into Schedule I.
Combo UTI drug can now treat costly pneumonias
Combo UTI drug can now treat costly pneumonias
February 6, 2018
FDA approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of ceftazidime and avibactam (Avycaz) to include 2 types of pneumonia.
FDA issues new warning on liver disease drug
FDA issues new warning on liver disease drug
February 6, 2018
FDA is adding a Boxed Warning, its most prominent warning, on a liver disease medicine.
Cannabis-derived epilepsy drug on the horizon
Cannabis-derived epilepsy drug on the horizon
January 29, 2018
A pharmaceutical formulation of purified cannabidiol, a cannabinoid without euphoric side effects, is expected to launch in the second half of this year.
Blindness gene therapy price tag stirs controversy
Blindness gene therapy price tag stirs controversy
January 23, 2018
A patient advocacy group is criticizing the hefty price tag of a new treatment for blindness.
Survey uncovers lupus corticosteroid treatment issues
Survey uncovers lupus corticosteroid treatment issues
January 22, 2018
Patients with systemic lupus erythematosus often self-manage their corticosteroid medication without the consent of their healthcare providers, according to a recent multicountry survey.
FDA takes tough stance on kids’ opioid cold meds
FDA takes tough stance on kids’ opioid cold meds
January 16, 2018
FDA is taking its toughest stance yet on opioid-containing cough and cold medications for children.
FDA approves first drug for breast cancer with BRCA gene
FDA approves first drug for breast cancer with BRCA gene
January 16, 2018
FDA approved the first drug to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation.
Drug shortage help on horizon
Drug shortage help on horizon
January 8, 2018
While hospitals continue to face IV saline shortages after two hurricanes significantly damaged infrastructure in Puerto Rico, the situation should improve early this year.
© 2024 MJH Life Sciences

All rights reserved.